Pirtobrutinib Expands Options Potential Second-Line Option in CLL

Although pirtobrutinib (Jaypirca) is currently only indicated by the FDA for the treatment of patients with chronic lymphocytic leukemia (CLL) following at least 2 prior lines of treatment, the noncovalent could still have a role in the…